WEKO3
アイテム
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study
http://hdl.handle.net/10129/0002000922
http://hdl.handle.net/10129/00020009220a131067-e464-4fec-b6b4-cbce65505ebc
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
内容要旨 (261 KB)
|
|
|
|
審査要旨 (141 KB)
|
|
|
|
本文 (1.5 MB)
|
.png)
|
| Item type | リポジトリ登録用アイテムタイプ（シンプル）(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-06-11 | |||||||
| タイトル | ||||||||
| タイトル | Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study | |||||||
| 言語 | en | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子（シンプル） | http://purl.org/coar/resource_type/c_db06 | |||||||
| 資源タイプ（シンプル） | doctoral thesis | |||||||
| アクセス権 | ||||||||
| アクセス権 | open access | |||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||
| 著者 |
佐々木, 大地
× 佐々木, 大地
|
|||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Objectives To evaluate the effect of 6-cycle completion and earlier use of radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC). Methods We retrospectively evaluated 75 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and August 2021. The primary purpose of the study was to assess the effect of Ra223 completion (6 cycles) on patient prognosis, and the secondary purpose was to investigate factors associated with Ra223 incompletion (fewer than 6 cycles) and overall survival. Results The median age of the patients was 72 years. The median number of Ra223 administrations was 6 (interquartile range, 5–6), and the median Ra223 completion rate was 75%. The median time from mCRPC diagnosis to Ra223 administration was 17 months, and the median number of prior treatments was 2. Multivariable analysis indicated that unfavorable performance status (>0), prostate-specific antigen (PSA) level >10 ng/ml, extension of bone metastasis score 3 to 4, and Ra223 incompletion were significantly associated with poor overall survival. In addition, EOD 3 to 4 and 3 or more prior CRPC treatments were significantly associated with Ra223 incompletion. Conclusion Six-cycle completion and earlier administration of Ra233 are potentially associated with favorable survival. Unfavorable factors (EOD 3–4 and ≥3 prior treatments) were significantly associated with Ra223 incompletion. |
|||||||
| 書誌情報 |
en : Urologic Oncology: Seminars and Original Investigations 巻 40, 号 2, p. 64.e1-64.e8 |
|||||||
| DOI | ||||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | https://doi.org/10.1016/j.urolonc.2021.11.005 | |||||||
| 権利情報 | ||||||||
| 言語 | en | |||||||
| 権利情報 | © 2021 Elsevier Inc. All rights reserved. | |||||||
| 出版タイプ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| 出版者 | ||||||||
| 出版者 | ELSEVIER | |||||||
| 言語 | en | |||||||
| 学位名 | ||||||||
| 言語 | ja | |||||||
| 学位名 | 博士（医学） | |||||||
| 学位授与機関 | ||||||||
| 言語 | ja | |||||||
| 学位授与機関名 | 弘前大学 | |||||||
| 学位授与年月日 | ||||||||
| 学位授与年月日 | 2025-03-24 | |||||||
| 学位授与番号 | ||||||||
| 学位授与番号 | 甲第2306号 | |||||||
